Anti-Apolipoprotein CIII antibody [EP1372Y],Abcam,AB76305
The production method for this product has been changed from hybridoma to recombinant on 18th June 2024. Species reactivity Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents .
Host
Rabbit
Reactivity
Human
Application
WB
Platform ID
BAB963916622
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma (PubMed : 18201179, PubMed : 22510806). Plays a multifaceted role in triglyceride homeostasis (PubMed : 18201179, PubMed : 22510806). Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs) (PubMed : 18201179, PubMed : 22510806). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors (PubMed : 18201179, PubMed : 22510806). Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners (PubMed : 18408013). See full target information Apolipoprotein C-III
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
Please provide the required information below so that we can quickly source your products.